The Protective Effect of Myo-inositol on Human Thyrocytes

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2018 Dec 5

PMID 30511181

Citations 8

Authors

Silvia Martina Ferrari

Giusy Elia

Francesca Ragusa

Sabrina Rosaria Paparo

Claudia Caruso

Salvatore Benvenga

Poupak Fallahi

Alessandro Antonelli

Affiliations

Soon will be listed here.

Abstract

Patients affected by autoimmune thyroiditis reached positive effects on indices of thyroid autoimmunity and/or thyroidal function, after following a treatment with selenomethionine (Se) alone, or Se in combination with Myo-inositol (Myo-Ins). Our purpose was to investigate if Myo-Ins alone, or a combination of Se + Myo-Ins, is effective in protecting thyroid cells from the effects given by cytokines, or hydrogen peroxide (HO). We assessed the interferon (IFN)-γ-inducible protein 10 (IP-10/CXCL10) secretion by stimulating primary thyrocytes (obtained from Hashimoto's thyroiditis or from control patients) with cytokines in presence/absence of HO Our results confirm: 1) the toxic effect of HO in primary thyrocytes that leads to an increase of the apoptosis, to a decrease of the proliferation, and to a slight reduction of cytokines-induced CXCL10 secretion; 2) the secretion of CXCL10 chemokine induced by IFN-γ + tumor necrosis factor alpha (TNF)-α has been decreased by Myo + Ins, both in presence or absence of HO; 3) no effect has been shown by the treatment with Se. Therefore, a protective effect of Myo-Ins on thyroid cells has been suggested by our data, which exact mechanisms are at the basis of this effect need to be furtherly investigated.

Citing Articles

Exploring the potential of myo-inositol in thyroid disease management: focus on thyroid cancer diagnosis and therapy.

Razavi S, Kalari M, Haghzad T, Haddadi F, Nasiri S, Hedayati M Front Endocrinol (Lausanne). 2024; 15:1418956.

PMID: 39329107 PMC: 11424451. DOI: 10.3389/fendo.2024.1418956.

Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism.

Ferrari S, Ragusa F, Elia G, Paparo S, Mazzi V, Baldini E Front Pharmacol. 2021; 12:750380.

PMID: 34867359 PMC: 8635786. DOI: 10.3389/fphar.2021.750380.

The Association of Myo-Inositol and Selenium Contrasts Cadmium-Induced Thyroid C Cell Hyperplasia and Hypertrophy in Mice.

Benvenga S, Micali A, Ieni A, Antonelli A, Fallahi P, Pallio G Front Endocrinol (Lausanne). 2021; 12:608697.

PMID: 33716965 PMC: 7949001. DOI: 10.3389/fendo.2021.608697.

MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?.

Wu X, Yan F, Wang L, Sun G, Liu J, Qu M Front Cell Dev Biol. 2020; 8:812.

PMID: 32984321 PMC: 7493075. DOI: 10.3389/fcell.2020.00812.

Osmolyte-Induced Folding and Stability of Proteins: Concepts and Characterization.

Mojtabavi S, Samadi N, Faramarzi M Iran J Pharm Res. 2020; 18(Suppl1):13-30.

PMID: 32802087 PMC: 7393045. DOI: 10.22037/ijpr.2020.112621.13857.

References

Benhamou P, Moriscot C, Richard M, Beatrix O, Badet L, Pattou F . Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. Diabetologia. 1998; 41(9):1093-100. DOI: 10.1007/s001250051035. View

Chee R, Agah R, Vita R, Benvenga S . L-carnitine treatment in a seriously ill cancer patient with severe hyperthyroidism. Hormones (Athens). 2014; 13(3):407-12. DOI: 10.14310/horm.2002.1494. View

Antonelli A, Ferrari S, Frascerra S, Corrado A, Pupilli C, Bernini G . Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res. 2011; 317(11):1527-33. DOI: 10.1016/j.yexcr.2011.04.007. View

Chiaradia E, Gaiti A, Scaringi L, Cornacchione P, Marconi P, Avellini L . Antioxidant systems and lymphocyte proliferation in the horse, sheep and dog. Vet Res. 2002; 33(6):661-8. DOI: 10.1051/vetres:2002047. View

Liao F, Rabin R, Yannelli J, Koniaris L, Vanguri P, Farber J . Human Mig chemokine: biochemical and functional characterization. J Exp Med. 1995; 182(5):1301-14. PMC: 2192190. DOI: 10.1084/jem.182.5.1301. View

Antonelli A, Ferrari S, Frascerra S, Galetta F, Franzoni F, Corrado A . Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011; 55(2):288-93. DOI: 10.1016/j.cyto.2011.04.022. View

Gartner R, Gasnier B, Dietrich J, Krebs B, Angstwurm M . Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002; 87(4):1687-91. DOI: 10.1210/jcem.87.4.8421. View

Kimura S, YONEMURA T, Kaya H . Increased oxidative product formation by peripheral blood polymorphonuclear leukocytes in human periodontal diseases. J Periodontal Res. 1993; 28(3):197-203. DOI: 10.1111/j.1600-0765.1993.tb01069.x. View

Antonelli A, Ferrari S, Frascerra S, Pupilli C, Mancusi C, Metelli M . CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab. 2010; 95(12):E413-20. DOI: 10.1210/jc.2010-0923. View

10.

Nordio M, Pajalich R . Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. J Thyroid Res. 2013; 2013:424163. PMC: 3809375. DOI: 10.1155/2013/424163. View

11.

Antonelli A, Ferri C, Fallahi P, Ferrari S, Frascerra S, Sebastiani M . High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008; 42(1):137-43. DOI: 10.1016/j.cyto.2008.01.002. View

12.

Janero D, Hreniuk D, Sharif H . Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte): lethal peroxidative membrane injury. J Cell Physiol. 1991; 149(3):347-64. DOI: 10.1002/jcp.1041490302. View

13.

Kashiwada M, Lu P, Rothman P . PIP3 pathway in regulatory T cells and autoimmunity. Immunol Res. 2007; 39(1-3):194-224. DOI: 10.1007/s12026-007-0075-2. View

14.

Marcocci C, Kahaly G, Krassas G, Bartalena L, Prummel M, Stahl M . Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011; 364(20):1920-31. DOI: 10.1056/NEJMoa1012985. View

15.

Riou C, Remy C, Rabilloud R, Rousset B, Fonlupt P . H2O2 induces apoptosis of pig thyrocytes in culture. J Endocrinol. 1998; 156(2):315-22. DOI: 10.1677/joe.0.1560315. View

16.

Marx N, Mach F, Sauty A, Leung J, Sarafi M, Ransohoff R . Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000; 164(12):6503-8. PMC: 4231715. DOI: 10.4049/jimmunol.164.12.6503. View

17.

Gulcin I . Antioxidant and antiradical activities of L-carnitine. Life Sci. 2005; 78(8):803-11. DOI: 10.1016/j.lfs.2005.05.103. View

18.

Ademoglu E, Ozbey N, Erbil Y, Tanrikulu S, Barbaros U, Yanik B . Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med. 2006; 17(8):545-50. DOI: 10.1016/j.ejim.2006.04.013. View

19.

Luster A, Jhanwar S, Chaganti R, Kersey J, Ravetch J . Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells. Proc Natl Acad Sci U S A. 1987; 84(9):2868-71. PMC: 304761. DOI: 10.1073/pnas.84.9.2868. View

20.

Benvenga S, Amato A, Calvani M, Trimarchi F . Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci. 2004; 1033:158-67. DOI: 10.1196/annals.1320.015. View